Applied Genetic Technologies Corporation announced the appointment of Janet C. Rae, RAC, as Senior Vice President of Global Regulatory and Quality. The appointment of Ms. Rae, who will join AGTC on June 18, 2021, is an important step in the Company’s strategy to prepare for anticipated late-stage development of its X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM) programs. She will be instrumental in assuring regulatory compliance as the company initiates its previously announced plans to lease a build-to-suit 21,000 square foot current Good Manufacturing Practices (cGMP) manufacturing and quality control facility adjacent to its Florida facility. Ms. Rae brings nearly 30 years of experience in the regulatory affairs industry across drug, biologic and gene therapy products with a specialization in orphan drugs and rare disease therapy development. Most recently, she served as Vice President, Head of Regulatory Affairs for Gene Therapy at Ultragenyx Pharmaceutical Inc., where she was accountable for the development and oversight of global regulatory strategies and related regulatory operations across the company’s gene therapy portfolio of products. Prior to joining Ultragenyx, she held positions at Dimension Therapeutics, Shire, Bentley Pharmaceuticals and PAREXEL International.